Welcome to our dedicated page for Viemed Healthcare news (Ticker: VMD), a resource for investors and traders seeking the latest updates and insights on Viemed Healthcare stock.
The Viemed Healthcare, Inc. (VMD) news page on Stock Titan aggregates company-specific updates for investors and observers who follow in-home post-acute respiratory care and home medical equipment providers. Viemed’s public communications describe it as a national leader in technology-enabled, in-home clinical care focused on non-invasive ventilation and related respiratory therapies in the United States.
News items for Viemed commonly include quarterly and year-to-date financial results, where the company reports revenue, net income, adjusted EBITDA, cash flow, and balance sheet data. These earnings releases, often furnished to the SEC on Form 8-K, are accompanied by financial supplements and sometimes updated full-year guidance ranges. They also highlight trends in ventilator, PAP therapy, and sleep resupply patient counts, as well as commentary from management on operating performance.
Another important category of news involves strategic transactions and capital allocation. Recent press releases have covered the authorization and completion of a share repurchase program, including the total number of shares repurchased and aggregate purchase price. Viemed has also announced the completion of its acquisition of Lehan’s Medical Equipment, an Illinois-based provider of home medical equipment with a focus on women’s health products and respiratory devices, and has discussed how this acquisition fits within its broader platform.
Visitors to this page can also expect updates about credit facility amendments, investor presentations, and conference appearances, which are often disclosed through Form 8-K filings and press releases. Together, these news items provide a view into Viemed’s operating trends, service diversification, financing arrangements, and outreach to the investment community. For anyone tracking VMD, this page serves as a centralized feed of the company’s official announcements and related coverage.
Stonegate Capital Partners initiated coverage on Viemed Healthcare (NASDAQ: VMD) on January 6, 2026.
Viemed is described as a leading U.S. provider of in-home post-acute respiratory care focused on non-invasive ventilation (NIV) for COPD and chronic respiratory failure, operating a clinician-driven model with respiratory therapists, proprietary workflows, and continuous monitoring.
Key disclosed metrics include 15 consecutive quarters of organic growth and management guidance implying approximately 20% year-over-year revenue growth and about 22% EBITDA margins. The firm has diversified into sleep therapy and resupply, oxygen therapy, staffing, and maternity care to broaden its platform.
Viemed Healthcare (NASDAQ:VMD) reported third quarter 2025 results for the three and nine months ended September 30, 2025. Q3 net revenue reached a company record of $71.9M, up 24.0% year-over-year. Net income for Q3 was $3.5M or $0.09 per diluted share. Adjusted EBITDA totaled $16.1M, a 15.5% increase versus prior year.
Cash flow: operating cash flow was $18.4M for the quarter and $48.5M TTM; free cash flow was $12.4M for the quarter and $23.3M TTM.
Corporate actions: closed acquisition of Lehan's Medical Equipment on July 1, 2025; repurchased 1,706,380 shares for $11.4M. Balance sheet: cash $11.1M, working capital $5.8M, long-term debt $19.6M. 2025 guidance updated to $271M–$273M revenue and $60M–$62M adjusted EBITDA.
Viemed Healthcare (NASDAQ:VMD) will host its Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025 at 11:00 a.m. ET. Participants can join by phone at (877) 407-6176 (US toll-free) or +1 (201) 689-8451 (international), or via live audio webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=asCOlSnC. A replay will be available in the Investor Relations section of Viemed's website at https://www.viemed.com. The call covers Viemed's Q3 2025 results and related commentary for investors and analysts.
Viemed Healthcare (NASDAQ: VMD) will present at the LD Micro Main Event XIX on Tuesday, October 21, 2025 at 11:00 AM PT at Hotel del Coronado in San Diego. Trae Fitzgerald, chief financial officer, will cover operational priorities, financial performance, and strategic direction. Management will be available for one-on-one investor meetings during the three-day conference.
The Main Event runs October 19–21, 2025, features roughly 120 companies presenting in half-hour slots, and includes keynotes, private investor meetings, and a closing reception. Investors can register to watch Viemed's virtual presentation.
Viemed Healthcare (NASDAQ:VMD), a leader in home-based post-acute respiratory care, has completed its share repurchase program announced on June 9, 2025. The company successfully repurchased and cancelled all 1,976,441 authorized common shares, representing approximately 5% of total outstanding shares.
The repurchase was executed at a weighted average price of $6.69 per share, totaling approximately $13.2 million. CEO Casey Hoyt emphasized that this program completion reflects the company's confidence in its long-term outlook and commitment to shareholder value, supported by strong balance sheet and increasing free cash flow.
Viemed Healthcare (NASDAQ:VMD) reported strong Q2 2025 financial results, with record net revenues of $63.1 million, up 14.7% year-over-year. Net income reached $3.2 million ($0.08 per diluted share), a 115.1% increase from Q2 2024. The company's Adjusted EBITDA grew 11.5% to $14.3 million.
Operational highlights include significant patient growth, with ventilator patients up 11.4% to 12,152 and PAP therapy patients increasing 51.4% to 26,260. The company completed a $26 million acquisition of Lehan's Medical Equipment on July 1, 2025. Viemed raised its 2025 guidance, now expecting revenue between $271-277 million and Adjusted EBITDA of $59-62 million.
The company maintains a strong financial position with $20 million in cash and $55 million available in credit facilities.
Viemed Healthcare (NASDAQ:VMD), a provider of post-acute respiratory healthcare equipment and services in the United States, has scheduled its Second Quarter 2025 Earnings Conference Call for Thursday, August 7, 2025, at 11:00 a.m. EDT.
Participants can join via phone using US Toll-Free (877) 407-6176 or International +1 (201) 689-8451. A live audio webcast will be available, and a replay will be accessible through the company's investor relations website after the call.
Viemed Healthcare (NASDAQ:VMD) has completed the acquisition of Illinois-based Lehan's Medical Equipment for a base purchase price of $26 million, plus estimated contingent payments of $2.2 million. Lehan, with an 80-year history, generated $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024.
The acquisition strengthens Viemed's presence in post-acute respiratory healthcare, adding Lehan's three full-service locations in Northern Illinois and three sleep/CPAP setup locations in West Chicagoland and Wisconsin. Viemed plans to update its full-year 2025 guidance to reflect the acquisition's contribution when reporting Q2 2025 results.
[ "Acquisition adds $25.7M in revenue and $7.4M in Adjusted EBITDA from Lehan's 2024 performance", "Expands geographical footprint with 6 new locations in Illinois and Wisconsin", "Gains access to Lehan's preferred contracts and 80-year brand recognition", "Enhances service offerings with addition of women's health products and CPAP services" ]